Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States from 1975 to 2005
Overview
Affiliations
Purpose: Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. Incidence rates are increasing in the United States. Monitoring incidence, survival, and mortality rates within at-risk populations can facilitate control efforts.
Methods: Age-adjusted incidence trends for HCC were examined in the Surveillance, Epidemiology, and End Results (SEER) registries from 1975 to 2005. Age-specific rates were examined for birth cohorts born between 1900 and 1959. Age-adjusted incidence and cause-specific survival rates from 1992 to 2005 were examined in the SEER 13 registries by race/ethnicity, stage, and treatment. United States liver cancer mortality rates were also examined.
Results: Age-adjusted HCC incidence rates tripled between 1975 and 2005. Incidence rates increased in each 10-year birth cohort from 1900 through the 1950s. Asians/Pacific Islanders had higher incidence and mortality rates than other racial/ethnic groups, but experienced a significant decrease in mortality rates over time. From 2000 to 2005, marked increases in incidence rates occurred among Hispanic, black, and white middle-aged men. Between 1992 and 2004, 2- to 4-year HCC survival rates doubled, as more patients were diagnosed with localized and regional HCC and prognosis improved, particularly for patients with reported treatment. Recent 1-year survival rates remained, however, less than 50%.
Conclusion: HCC incidence and mortality rates continue to increase, particularly among middle-aged black, Hispanic, and white men. Screening of at-risk groups and treatment of localized-stage tumors may contribute to increasing HCC survival rates in the United States. More progress is needed.
Lin H, Jeon A, Chen K, Lee C, Wu L, Chong S Br J Cancer. 2025; .
PMID: 40057667 DOI: 10.1038/s41416-025-02969-8.
Huy D, Khai N, Thinh T, Linh B, Minh N, Thuy V Mol Biotechnol. 2025; .
PMID: 39998774 DOI: 10.1007/s12033-025-01401-z.
Chang B, Tian H, Huang A, Zhai X, Wang Q, Han L eGastroenterology. 2025; 2(1):e100036.
PMID: 39944749 PMC: 11731072. DOI: 10.1136/egastro-2023-100036.
Diagnostic Performance of PIVKA-II in Italian Patients with Hepatocellular Carcinoma.
Guarneri V, Loggi E, Ramacieri G, Serra C, Vukotic R, Vitale G Cancers (Basel). 2025; 17(2).
PMID: 39857948 PMC: 11763969. DOI: 10.3390/cancers17020167.
Transcriptomic landscape of Hras12V oncogene-induced hepatocarcinogenesis with gender disparity.
Di H, Rong Z, Mao N, Li H, Chen J, Liu R BMC Cancer. 2025; 25(1):94.
PMID: 39819515 PMC: 11737189. DOI: 10.1186/s12885-025-13476-7.